ATCC

The continual spread of deadly viruses necessitates the development of novel prevention and treatment options; however, the development of a new antiviral vaccine can be challenged by low-yielding manufacturing processes. Similarly, the development of gene therapies is constrained during the large-scale production of adeno-associated virus (AAV) delivery platforms for gene transfer.

To speed the pace of these various areas of bioproduction, ATCC addressed the need for efficient viral replication by optimizing three cell lines commonly used in virus manufacturing. Here, we used CRISPR/Cas9 gene-editing technology to develop STAT1 and BAX knockout cell lines capable of producing high-titer viral stocks. These newly created cell lines can produce model clinical viruses and adeno-associated viruses at titers much higher than the parental cell lines, providing an efficient method for biopharmaceutical companies to increase production while reducing associated costs.  Discover how these advanced biological models can be used in your vaccine and gene therapeutic development projects.